<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789292</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P17 3.1</org_study_id>
    <secondary_id>2018-001690-25</secondary_id>
    <nct_id>NCT03789292</nct_id>
  </id_info>
  <brief_title>A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 With Humira When Co-administered With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients
      With Active Rheumatoid Arthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal
      antibody that is being developed as a similar biological medicinal product to Humira. The
      purpose of this study is to demonstrate similar efficacy and safety of CT-P17 and Humira in
      patients with moderate to severe rheumatoid arthritis when co-administered with methotrexate.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response according to the ACR definition of a 20% improvement (ACR20)</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients achieving clinical response (according to the ACR20 criteria)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CT-P17 Subcutaneous(SC) (adalimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P17 SC (adalimumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira SC (adalimumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humira SC (adalimumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P17 SC</intervention_name>
    <description>Subcutaneous injection of Adalimumab 40mg every two weeks</description>
    <arm_group_label>CT-P17 Subcutaneous(SC) (adalimumab)</arm_group_label>
    <arm_group_label>Humira SC (adalimumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humira SC</intervention_name>
    <description>Subcutaneous injection of Adalimumab 40mg every two weeks</description>
    <arm_group_label>Humira SC (adalimumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female aged 18 to 75 years old, both inclusive.

          -  Patient has had a diagnosis of rheumatoid arthritis according to the 2010 ACR/EULAR
             classification criteria for at least 24 weeks prior to the first administration of the
             study drug .

        Exclusion Criteria:

          -  Patient who has previously received investigational or licensed product; biologic or
             targeted synthetic disease-modifying antirheumatic drugs for the treatment of
             rheumatoid arthritis and/or a tumor necrosis factor (TNF) Î± inhibitor for any
             purposes.

          -  Patient who has allergies to any of the excipients of study drug or any other murine
             and human proteins, or patient with a hypersensitivity to immunoglobulin products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Multiprofile Transport Hospital Tsar Boris III</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2018</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

